Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
SEOUL, Sept 23 (Reuters) - Celltrion Inc. 068270.KS said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million.
In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner.
After upgrades and expansions to the facility, both key products the company sells in the United States and future launches will be shielded early from U.S. tariff exposure.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

Tradingkey






